Despite over 20 years of pharmaceutical targeted research, no antagonist of inflammatory chemokine receptors (iCCR) has been licensed for use in treating inflammatory diseases. Marked promiscuity of ligand binding, simultaneous expression of multiple chemokine receptors in indiv…
"1" Result
Sort By: